Halix begins viral vector production at new Dutch GMP facility

The new 6,700 sqm cGMP facility is in Leiden Bio Science Park just north of Rotterdam

Halix is building a viral vector and viral vaccine manufacturing facility in the Netherlands. The CDMO of clinical and commercial proteins and viral products has announced that they have met their major milestone with the interim delivery of their new 6,700 sqm cGMP facility in Leiden Bio Science Park just north of Rotterdam.

According to Alex Huybens, Halix COO, after a construction time of just 12 months, the company can now begin production of viral products, and protein production will follow soon. He explained that the aggressive timeline in order to meet market demands.

Now one year into construction, Halix has completed its new state-of-the-art cGMP facility for the development and production of biopharmaceutical drug substances.

The new five-level production facility contains a state-of-the-art manufacturing line for viral vaccines and viral vectors and a separate protein manufacturing area with a capacity up to 1,000 Liter single-use bioreactors.

In addition, lab space is available for process development, analytical development and quality control.

All cleanroom areas have a unidirectional process flow and are designed to allow commercial manufacturing of biopharmaceuticals products.

Roland Hecht, HALIX Chief Customer Officer said: “This new facility offers our current and future clients capacity and flexibility for future expansion and will allow for cGMP manufacturing solutions for viral products, proteins, gene therapy and client-specific new technologies.”

Companies